Diagnosis, treatment, and management of irritable bowel dyndrome with constipation and chronic constipation

MedGenMed Medscape General Medicine

Volumn 7, Issue 3, 2005, Pages

  Frissora, Christine L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALOSETRON; ANALGESIC AGENT; ANTACID AGENT; ANTIDEPRESSANT AGENT; BULKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILANSETRON; CISAPRIDE; CLONIDINE; COLESTYRAMINE; DIURETIC AGENT; ISPAGULA; LAXATIVE; LEVODOPA; LUBIPROSTONE; METAL; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OSMOTIC AGENT; PLACEBO; PSYCHOTROPIC AGENT; RENZAPRIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; SPASMOLYTIC AGENT; TEGASEROD; UNINDEXED DRUG;

ABDOMINAL CRAMP; ANORECTAL PRESSURE; ARTICLE; CLINICAL TRIAL; COLONOSCOPY; COMORBIDITY; CONSTIPATION; DEFECATION HABIT; DEFECOGRAPHY; DEHYDRATION; DIARRHEA; DIETARY FIBER; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG INDUCED HEADACHE; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL MOTILITY; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; HYPOVOLEMIA; IRRITABLE COLON; ISCHEMIC COLITIS; LIMB MALFORMATION; LOW DRUG DOSE; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT REFERRAL; POLYPHARMACY; PRACTICE GUIDELINE; QT PROLONGATION; QUALITY OF LIFE; SYMPTOMATOLOGY; SYNCOPE; SYSTEMATIC REVIEW; CHRONIC DISEASE; REVIEW;

CHRONIC DISEASE; CONSTIPATION; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 33750347257     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(suppl):S1-S5.
2. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(suppl):S7-S26.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppIII):1143-1147.
4. Brandt LJ. Irritable bowel syndrome expert column: on the relationship between colon ischemia, irritable bowel syndrome, and serotonergic therapy of irritable bowel syndrome. New York, NY: WebMD Medscape Health Network; 2004.
5. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108-2131. Abstract
6. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther. 1997;11:3-15.
7. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology. 2002;123:2105-2107. Abstract
8. Mearin F, Baro E, Roset M, Badia X, Zarate N, Perez I. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroenterol. 2004;99:113-121. Abstract
9. Toner BB, Akman D. Gender role and irritable bowel syndrome: literature review and hypothesis. Am J Gastroenterol. 2000;95:11-16. Abstract
10. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99:750-759. Abstract
11. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med. 1995;122:107-112. Abstract
12. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997;112:2120-2137. Abstract
13. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140-1156.
14. Kennedy TM, Jones RH, Hungin AP, O'Flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 1998;43:770-774. Abstract
15. Gershon MD. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. 2004;20:3-14.
16. Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care. 2001;7 (suppl):S252-S260.
17. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol. 2005;39(suppl3):S184-S193.
18. Talley NJ. Serotoninergic neuroenteric modulators. Lancet. 2001;358:2061-2068. Abstract
19. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004;126:1657-1664. Abstract
20. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology. 2003;124:1662-1671. Abstract
21. Thevarajah S, Polanecsky M, Scherl EJ, Frissora CL. Hormonal influences on the gastrointestinal tract and irritable bowel syndrome. Practical Gastroenterol. 2005;May:62-74.
22. Herz MJ, Kahan E, Zalevski S, Aframian R, Kuznitz D, Reichman S. Constipation: a different entity for patients and doctors. Fam Pract. 1996;13:156-159. Abstract
23. Arce DA, Ermocilla CA, Costa H. Evaluation of constipation. Am Fam Physician. 2002;65:2283-2290. Abstract
24. Talley N, O'Keefe E, Zinsmeister A, Melton LJ III. Prevalence of gastrointestinal symptoms in the elderly: a population based study. Gastroenterology. 1992;102:895-901. Abstract
25. Sandler RS, Drossman DA. Bowel habits in young adults not seeking health care. Dig Dis Sci 1987;32:841-845. Abstract
26. Velio P, Bassotti G. Chronic idiopathic constipation: pathophysiology and treatment. J Clin Gastroenterol. 1996;22:190-196. Abstract
27. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360-1368. Abstract
28. National Digestive Diseases Information Clearinghouse. Constipation. Bethesda, Md: National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2004.
29. Garrigues V, Galvez C, Ortiz V, Ponce M, Nos P, Ponce J. Prevalence of constipation: agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population based survey in Spain. Am J Epidemiol. 2004;159:520-526. Abstract
30. Johanson JF. Geographic distribution of constipation in the United States. Am J Gastroenterol. 1998;93:188-191. Abstract
31. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut. 1999;45:1137-1142. Abstract
32. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002;122:1701-1714. Abstract
33. Mahmood Z, Scheuner S, Gamborone J, Lavin F, O'Donnell LJD. Knowledge of the irritable bowel syndrome in patients and the general public. Irish J Med Sci. 1997;166:15.
34. Verne GN. The public awareness of the prevalence and impact of irritable bowel syndrome in the United States: perception versus reality. J Clin Gastroenterol. 2004;38:419-424. Abstract
35. Lembo TJ, Fink RN. Clinical assessment of irritable bowel syndrome. J Clin Gastroenterol. 2002;35:S31-S36. Abstract
36. Agreus L. The epidemiology of functional gastrointestinal disorders. Eur J Surg Suppl. 1998;(583):60-66. Abstract
37. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133:136-147. Abstract
38. Kellow JE. Treatment goals in irritable bowel syndrome. Int J Clin Pract. 2001;55:546-551. Abstract
39. Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7:87-92. Abstract
40. Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci. 2002;47:2222-2230. Abstract
41. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther. 1994;8:409-416. Abstract
42. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655-1666. Abstract
43. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16:1877-1888. Abstract
44. Zelnorm (tegaserod maleate) tablets. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004.
45. Mueller-Lissner S, Holtmann G, Loeffler H, Rueegg P. Tegaserod is effective in the retreatment of irritable bowel syndrome with constipation (IBS-C). Gastroenterology. 2003;124(suppl1):A-574.
46. Joelsson BE, Shetzline MA, Cunningham S. Ischemic colitis associated with use of tegaserod [reply]. N Engl J Med. 2004;351:1363-1364.
47. Singh G, Mithal A, Triadafilopoulos G. Patients with irritable bowel syndrome have a high-risk of developing ischemic colitis. Gastroenterology. 2004;126:A41-A42.
48. Cole JA, Cook SF, Sands BE, Ajene AN, Miller DP, Walker AM. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol. 2004;99:486-491. Abstract
49. George A, Meyers NL, Palmer RMJ. Efficacy and safety of renzapride in patients with constipation-predominant IBS: a phase llb study in the uk primary healthcare setting. Gut. 2003;52:A91.
50. Camilleri M, McKinzie S, Fox J, et al. Renzapide accelerates colonic transit and improves bowel function in constipation-predominant irritable bowel syndrome (C-IBS). Gastroenterology. 2004;126:A642.
51. Locke GR III, Pemberton JH, Phillips SF. American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology. 2000;119:1761-1766. Abstract
52. Rao SS. Constipation: evaluation and treatment. Gastroenterol Clin North Am. 2003;32:659-683. Abstract
53. Locke GR III, Pemberton JH, Phillips SF. AGA technical review on constipation. Gastroenterology. 2000;119:1766-1778. Abstract
54. Brandt LJ, Schoenfeld P, Prather CM, Quigley EMM, Schiller LR, Talley NJ. Evidenced-based position statement on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100:S1-S21. Abstract
55. Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100:936-971. Abstract
56. Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol. 2002;97:1986-1993. Abstract
57. Pampati V, Fogel R. Treatment options for primary constipation. Curr Treatment Options Gastroenterol. 2004;7:225-233.
58. MiraLax (polyethylene glycol 3550). Braintree, Mass: Braintree Laboratories, Inc.; 2003.
59. Johanson JF, Wald A, Tougas G, et, al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol. 2004;2:796-805. Abstract
60. Kamm MA, Muller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol. 2005;100:362-372. Abstract
61. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology. 2004;126:A100.